null
Med-IQ Express Med-IQ Express

New Therapies for Secondary Progressive Multiple Sclerosis


This activity was developed by Med-IQ in collaboration with Duke Health.

Med-IQ      Duke Medicine
 

Released:
8/6/19
Expires:
8/5/20

Maximum Credits:

0.25
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Med-IQ Express Med-IQ Express
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
8/6/19

Expires:
8/5/20

Maximum Credits:
0.25
Med-IQ Express Med-IQ Express
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
8/6/19
Expires:
8/5/20


Maximum Credits:
0.25


Overview: This 15-minute accredited CME publication reviews the mechanisms of action and clinical data of 2 new approved therapies for active secondary progressive multiple sclerosis (SPMS). Highlights include a discussion on SPMS pathophysiology and how newer therapies may address both the inflammatory and degenerative aspects of the disease. In addition, this activity features a short video that provides expert commentary from Mark Skeen, MD, on the current management landscape for patients with SPMS.

CME Information:

Faculty
Mark B. Skeen, MD, FACP, FAAN
Associate Professor of Neurology
Head, Division of Multiple Sclerosis and Neuroimmunology
Department of Neurology
Duke University Medical Center
Durham, NC
 
Activity Planners
Iwona Misiuta, PhD, MHA
Clinical Content Manager
Med-IQ
Baltimore, MD
 
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI
 
Writer
Jill Roberts, MS
Missoula, MT
 
Learning Objective
Upon completion, participants should be able to:

  • Discuss the mechanisms of action and clinical data of novel FDA-approved therapies for active SPMS

Target Audience
This activity is intended for neurologists.
 
Statement of Need
Multiple sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease of the central nervous system characterized by heterogeneity in clinical presentation and disease course. It is estimated to affect 2.3 million people worldwide with a global median prevalence of 33 per 100,000. Although the cause of MS remains unknown, it is believed that genetic, environmental, and endogenous factors may contribute to disease development. Most patients (up to 85%) are initially diagnosed with relapsing-remitting MS (RRMS). Eventually, RRMS transitions into secondary progressive MS (SPMS) in more than 50% of patients. Recent clinical investigation has led to the development and approval of 2 new pharmaceutical therapies for patients with SPMS. This brief activity reviews historical treatment approaches for MS and explores these novel approaches for patients with the SPMS phenotype.

Collaboration Statement
This activity was developed by Med-IQ in collaboration with Duke Health.
 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: August 6, 2019
Expiration Date: August 5, 2020
Estimated Time to Complete This Activity: 15 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Mark B. Skeen, MD, FACP, FAAN
Salary: VeraSci
Consulting fees/advisory boards: Alexion, Biogen Idec, Celgene Corporation, EMD Serono, Inc., Genentech, Novartis Pharmaceuticals Corporation
Fees received for promotional/non-CME activities: Alexion, Biogen Idec, Celgene Corporation, EMD Serono, Inc., Genentech, Novartis Pharmaceuticals Corporation
 
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
 
Copyright
© 2019 Med-IQ, Inc. and Duke University Health System

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.